Please assess the completion status of the following clinical trial:

Trial Title: Lanreotide Autogel in the Symptomatic Treatment of Refractory Diarrhea

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male/female with refractory diarrhea for at least 1 month, after normal extended work-up to exclude causes of diarrhea, not or not enough responding to standard anti-diuretics as evaluated by the investigator~* Patient mentally fit for completing a diary~Exclusion Criteria:~* Has already received a treatment with somatostatin analogues for the treatment of refractory diarrhea~* Had a weight of stool \< 600g in a 72hrs stool collection~* Has received a treatment with laxatives within the last week before study entry~* Suffers from IBS with alternating bowel habits and predominant constipation, suffers from infectious and/or inflammatory gastro-enteritis (colitis ulcerosa, crohn's disease and macroscopic colitis)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- lanreotide (Autogel formulation) Autogel 120mg (Type: EXPERIMENTAL): lanreotide (Autogel formulation) Autogel 120mg

Based on this trial design, predict the completion outcome and termination type (if applicable).